AviadoBio Website
Founded 2019 · 72 employees on LinkedIn · 6 known investors
Find your way into AviadoBio Website
567 people in our graph share verified history with the AviadoBio Website team — schools, employers, funds. One of them is your warm intro.
Egilunlockedknows Graeme Fielder · together at University of Auckland (overlapped)
knows the team · via NYU Stern School of Business
knows the team · via King's College London
×3knows the team · via Chiasma
×3knows the team · via University of Notre Dame - Mendoza College of Business
knows the team · via InSITE
AviadoBio is a gene therapy company developing adeno-associated viral (AAV) treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). It is a spinout from King's College London research focused on the genetics and molecular biology of these diseases.
Founders & leadership
AviadoBio Website was founded in 2019 by Chris Shaw, Do Young Lee, and Youn Bok Lee.
CS
Chris ShawinCo-Founder & Chief Scientific and Clinical AdvisorChris Shaw is a neurologist and neurogeneticist with over 25 years of clinical and research experience in amyotrophic lateral sclerosis and frontotemporal dementia. He directs the Maurice Wohl Clinical Neurosciences Institute at King's College London and leads research that has identified multiple disease-associated genes; he co-founded AviadoBio to develop AAV-based gene therapy treatments for these neurodegenerative disorders.
DY
Do Young LeeCo-Founder
YB
Youn Bok LeeinCo-Founder
LD
Lisa DeschampsinChief Executive OfficerLisa Deschamps spent over 25 years at Novartis, including as Senior Vice President and Chief Business Officer of Novartis Gene Therapies, where she oversaw commercialization of gene therapy products including Zolgensma, and has held leadership roles across multiple therapeutic areas and global regions. She holds an MBA in General Management from NYU Stern School of Business and a BBA in Marketing from Iona University.
GF
Graeme FielderinChief Operating OfficerGraeme Fielder is a biomedical scientist with background in preclinical drug discovery and technology commercialization across biotech, agriculture, and food sectors. As Chief Operating Officer of AviadoBio, he works on developing genetic medicines for neurodegenerative diseases.
AB
Alex BloominChief Development Officer
DC
David CooperinChief Medical Officer
FS
Farah SpeerinSVP, Communications & External RelationsFarah Speer holds an MBA from the University of Notre Dame and a BS in mass communication from Boston University. She has held leadership roles in healthcare communications and marketing across pharmaceutical, biotech, and consumer healthcare organizations, with experience in FDA approval messaging, investor relations, and patient advocacy programs.
JI
John IsaacinChief Scientific Officer
Investors · 6
Frequently asked questions
- What does AviadoBio Website do?
- AviadoBio is a gene therapy company developing adeno-associated viral (AAV) treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). It is a spinout from King's College London research focused on the genetics and molecular biology of these diseases.
- Who founded AviadoBio Website?
- AviadoBio Website was founded by Chris Shaw, Do Young Lee, Youn Bok Lee in 2019.
- Who are AviadoBio Website's investors?
- AviadoBio Website's investors include Advent Life Sciences, Dementia Discovery, F-Prime Capital, LifeArc Ventures, Monograph Capital Partners, New Enterprise Associates (NEA).